On May 13, Cao Yuping, the controlling shareholder of Haichen Pharmaceutical (securities code: 300584), pledged 1.58 million shares to Huatai Securities (Shanghai) Asset Management Co., Ltd. for supplementary pledge.
1.58 million shares were pledged, accounting for 3.13% of the company’s shares and 1.32% of the company’s total share capital. The pledge period is from May 11, 2021 to August 11, 2021.
According to the announcement, Cao Yuping held 50491306 shares of the company, accounting for 42.08% of the total share capital of the company. A total of 26258000 shares have been pledged, accounting for 52% of its shares and 21.88% of the total share capital of the company.
According to the company’s report for the first quarter of 2021, the company’s net profit attributable to shareholders of Listed Companies in the first quarter of 2021 was 13509866.40 yuan, down 21.30% from the same period of last year.
Haichen pharmaceutical and its subsidiaries are mainly engaged in the R & D, production and sales of chemical preparations, APIs and intermediates. During the reporting period, the company’s main business and main products have not changed significantly.